Malignant Infratentorial Neoplasm — Trials

Malignant Infratentorial Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

302 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 99
Recruiting: 50
Ph III recruiting: 3
Growth YoY: —
Industry share: 9%
Top sponsor: National Cancer Institute (NCI)
Termination share: 37.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (46)

clinicaltrialsPublishedShowing 51–100 of 302 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04337177	Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors	active not recruiting	Phase 1	20	Valent Technologies, LLCINDUSTRY	1	Jul 30, 2026	clinicaltrials
NCT04743661	131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma	active not recruiting	Phase 2	62	Pediatric Brain Tumor ConsortiumNETWORK	1	Jul 28, 2026	clinicaltrials